Species distribution and antifungal susceptibility profile off Candida isolates from bloodstream infections in Lima, Peru

Journal of Medical Microbiology

Volumn 63, Issue PART 6, 2014, Pages 855-860

  Bustamante, B ^a   Martins, M A ^b   Bonfietti, L X ^b   Szeszs, M W ^b   Jacobs, J ^c   Garcia, C ^a   Melhem, M S C ^b  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c Department of Animal Health   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; EPSILOMETER TEST; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PERU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPECIES DISTRIBUTION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; HUMANS; PERU; SPECIES SPECIFICITY;

EID: 84901301399     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.071167-0     Document Type: Article

References (45)

1. Amran, F., Aziz, M. N., Ibrahim, H. M., Atiqah, N. H., Parameswari, S., Haiza, M. R. & I wat, M. (2011). In vitro antifungal susceptibilitieso Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol 60, 1312-1316.
2. Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaeldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E. & other authors (2013). Epidemiological changes with potential implication of antifungal prescription recommendations of ungaemia: data from a nationwide ungaemia surveillance programme. Clin Microbiol In ect 19, E343-E353.
3. Becerra, M. R., Tantaleán, J. A., Suárez, V. J., Alvarado, M. C., Candela, J. L. & Urcia, C. (2010). Epidemiologic surveillance of nosocomial infections in a Pediatric Intensive Care Unit of a developing country. BMC Pediatr 10, 66-74.
4. Bonietti, L. X., Szeszs, M. W., Chang, M. R., Martins, M. A., Pukinskas, S. R. B. S., Nunes, M. of., Pereira, G. H., Paniago, A. M. M., Purisco, S. U. & Melhem, M. S. G. (2012). Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital. Mycopathologia 174, 389-396.
5. Cleveland, A. A., arley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J. & Chiller, T. M. (2012). Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin In ect Dis 55, 1352-1361.
6. CLSI (2008a). Re erence Method of Broth Dilution Antifungal Susceptibility Testing of Yeasts; 3rd edn, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.
7. CLSI (2008b). Reference Method of Broth Dilution Antifungal Susceptibility Testing of Yeasts; 3rd edn, Informational Supplement M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute.
8. CLSI (2012). Reference Method of Broth Dilution Antifungal Susceptibility Testing of Yeasts; 4th informational supplement M27- S4. Wayne, PA: Clinical and Laboratory Standards Institute.
9. Córdoba, S., Melhem, M., Dolande, M., Puime, A., Martínez, G., Zurita, S., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. & Gabastou, J. M. RLN. (2012). Species distribution and susceptibility profile of yeasts isolated from blood cultures: preliminary results off a multicenter study of Latin America. In Abstracts of the ICAAC, abstract M- 327. Washington, DC: American Society of Microbiology.
10. Costa, S., Marinho, I., Araújo, E. A. P., Manrique, A. E. I., Medeiros, E. A. S. & Levin, A. S. (2000). Nosocomial ungaemia: a 2-year prospective study. J Hosp In ect 45, 69-72.
11. Cruz, R. & Piontelli, E. (2011). [Invasive ungal disease in patients from five hospitals in the Valparaiso region, Chile. 2004 to 2009]. Rev Chilena Infectol 28, 123-129 (in Spanish).
12. Cuenca-Estrella, M., Gomez-Lopez, A., Cuesta, I., Zaragoza, of., Mellado, E. & Rodriguez-Tudela, J. L. (2011). Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. according to breakpoints established by the Antifungal Subcommittee of the European Committee ofn Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 55, 1794-1797.
13. Erdem, I., ofguzoglu, N., ofzturk Engin, D., ofzgultekin, A., Sengoz Inan, A., Ceran, N., Kaya, F., Genc, I. & Goktas, P. (2010). Incidence, etiology and risk actors associated with mortality of nosocomial candidemia in a tertiary care hospital in Istanbul, Turkey. Med Princ Pract 19, 463-467.
14. Jang, M. J., Shin, J. H., Lee, W. G., Kim, M. N., Lee, K., Lee, H. S., Lee, M. K., Chang, C. L., Jang, H. C. & other authors (2013). In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cuto values. Ann Lab Med 33, 167-173.
15. Jung, S.-I., Shin, J. H., Song, J.-H., Peck, K. R., Lee, K., Kim, M.-N., Chang, H. H., Moon, C. S. &The Korean Study Group of Candidemia (2010). Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 48, 669-674.
16. Kovacicova, G., Hanzen, J., Pisarcikova, M., Sejnova, D., Horn, J., Babela, R., Svetlansky, I., Lovaszova, M., Gogova, M. & Krcmery, V. (2001). Nosocomial ungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery of brain tumors. J In ect Chemother 7, 45-48.
17. Labbé, A. C., Pépin, J., Patiño, C., Castonguay, S., Restieri, C. & Laverdiere, M. (2009). A single-centre 10-year experience with Candida bloodstream infections. Can J In ect Dis Med Microbiol 20, 45-50.
18. Lee, I., ishman, N. of., Zaoutis, T. E., Morales, K. H., Weiner, M. G., Synnestvedt, M., Nachamkin, I. & Lautenbach, E. (2009). Risk actors of fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 169, 379-383.
19. Levy, I., Rubin, L. G., Vasishtha, S., Tucci, V. & Sood, S. K. (1998). Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin In ect Dis 26, 1086-1088.
20. Lockhart, S. R., Messer, S. A., Pfaller, M. A. & Diekema, D. J. (2008). Geographic distribution and antifungal susceptibility of the newly described species Candida ofthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46, 2659-2664.
21. Lockhart, S. R., Iqbal, N., Cleveland, A. A., arley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R. & other authors (2012). Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50, 3435-3442.
22. Luo, G. & Mitchell, T. G. (2002). Rapid identification of pathogenic ungi directly from cultures by using multiplex PCR. J Clin Microbiol 40, 2860-2865.
23. Ma, C.F., Li, F.Q., Shi, L. N., Hu, Y. A., Wang, Y., Huang, M. & Kong, Q. Q. (2013). Surveillance study off species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC In ect Dis 13, 337-345.
24. Mannarelli, B. M. & Kurtzman, C. P. (1998). Rapid identification of Candida albicans and other human pathogenic yeasts by using short ofligonucleotides in a PCR. J Clin Microbiol 36, 1634-1641.
25. Miranda-Zapico, I., Eraso, E., Hernández-Almaraz, J. L., López- Soria, L. M., Carrillo-Muñoz, A. J., Hernández-Molina, J. M. & Quindós, G. (2011). Prevalence and antifungal susceptibility patterns of nfew cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J Antimicrob Chemother 66, 2315-2322.
26. Nishikaku, A. S., Melo, A. S. A. & Colombo, A. L. (2010). Geographic trends in invasive candidiasis. Curr ungal In ect Rep 4, 210-218.
27. Nucci, M., Queiroz-Telles, F., Alvarado-Matute, T., Tiraboschi, I. N., Cortes, J., Zurita, J., Guzman-Blanco, M., Santolaya, M. E., Thompson, L. & other authors (2013). Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ofNE 8, e59373.
28. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauman, C. A. & other authors (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47, 3149-3154.
29. Pappas, P. G., Kau man, C. A., Andes, D., Benjamin, D. K., Jr, Calandra, T., Edwards, J. E., Jr, iller, S. G., isher, J., Kullberg, B.-J. & other authors (2009). Clinical practice guidelines of the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin In ect Dis 48, 503-535.
30. Park, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D. & other authors (2006). Evaluation of amphotericin B interpretive breakpoints of Candida bloodstream isolates by correlation with therapeutic ofutcome. Antimicrob Agents Chemother 50, 1287-1292.
31. Paz Rojas, E. L., de León Pandoli, D. P. & Ramírez Ponce, R. (2008). [Antimicrobial resistance in an intensive care unit and current trends: Critical Care Department, IntensiveCare Service of Guillermo Almenara-Irigoyen National Hospital, EsSalud, Lima, Peru, 2004- 2006.] Acta méd peruana 25, 140-147 (in Spanish).
32. Pemán, J., Cantón, E., Quindós, G., Eraso, E., Alcoba, J., Guinea, J., Merino, P., Ruiz-Pérez-de-Pipaon, M. T., Pérez-del-Molino, L. & other authors (2012). Epidemiology, species distribution and in vitro antifungal susceptibility of ungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 67, 1181-1187.
33. Pereira, G. H., Müller, P. R., Szeszs, M. W., Levin, A. S. & Melhem, M. S. C. (2010). Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 48, 839-842.
34. Paller, M. A. & Diekema, D. J. (2002). Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40, 3551-3557.
35. Pfaller, M. A. & Diekema, D. J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133-163.
36. Pfaller, M. A. & Diekema, D. J. (2012b). Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50, 2846-2856.
37. Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S. & Diekema, D. J. (2006). In vitro susceptibilities of Candida spp. to caspo ungin: four years of global surveillance. J Clin Microbiol 44, 760-763.
38. Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodlo, A.u.W., Ling, T. A. & Global Antifungal Surveillance Group (2010). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk di usion. J Clin Microbiol 48, 1366-1377.
39. Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A. & Jones, R. N. (2012a). Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50, 1199-1203.
40. Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N. & Castanheira, M. (2013). Echinocandin and triazole antifungal susceptibility profiles of clinical ofpportunistic yeast and mold isolates collected from 2010 to 2011: application of nfew CLSI clinical breakpoints and epidemiological cuto values of characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51, 2571-2581.
41. Porte, L., León, P., Gárate, C., Guzmán, A. M., Labarca, J. & García, P. (2012). [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010.] Rev Chilena Infectol 29, 149-155 (in Spanish).
42. Rodero, L., Davel, G., Soria, M., Vivot, W., Córdoba, S., Canteros, C. E., Saporiti, A. & Emi N (2005). [Multicenter study of ungemia due to yeasts in Argentina]. Rev Argent Microbiol 37, 189-195 (in Spanish).
43. Sampaio Camargo, T. Z., Marra, A. R., Silva, C. V., Cardoso, M., Martino, M. D., Camargo, L. & Correa, L. (2010). Secular trends of candidemia in a tertiary care hospital. Am J In ect Control 38, 546-551.
44. Tavanti, A., Davidson, A. D., Gow, N. A., Maiden, M. C. J. & ofdds, C. (2005). Candida ofthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43, 284-292.
45. Wanger, A., Mills, K., Nelson, P. W. & Rex, J. H. (1995). Comparison of Etest and National Committee of Clinical Laboratory Standards broth macrodilution method of antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 39, 2520-2522.